"PPAR delta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nuclear transcription factor. It is activated by PROSTACYCLIN.
| Descriptor ID |
D047494
|
| MeSH Number(s) |
D12.776.826.239.555
|
| Concept/Terms |
PPAR delta- PPAR delta
- PPARdelta
- Peroxisome Proliferator-Activated Receptor delta
- Peroxisome Proliferator Activated Receptor delta
- PPARD protein
|
Below are MeSH descriptors whose meaning is more general than "PPAR delta".
Below are MeSH descriptors whose meaning is more specific than "PPAR delta".
This graph shows the total number of publications written about "PPAR delta" by people in this website by year, and whether "PPAR delta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "PPAR delta" by people in Profiles.
-
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):783-794.
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):795-805.
-
PPARd dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric Cancer. 2023 11; 26(6):904-917.
-
Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARd. Nat Commun. 2022 05 13; 13(1):2665.
-
Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis. Pathology. 2022 Oct; 54(6):686-693.
-
Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. Int J Mol Sci. 2022 Jan 31; 23(3).
-
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
-
PPARd Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. Mol Cancer Res. 2020 03; 18(3):390-402.
-
Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Res. 2019 03 01; 79(5):954-969.
-
The Role of PPAR-d in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor. Int J Mol Sci. 2018 Oct 26; 19(11).